Remoxiprid versus haloperidol i behandlingen af skizofreni En dobbelt-blind sammenlignende undersøgelse af remoxiprid og haloperidol i behandlingen af skizofreni

A multicenter, double-blind controlled study was carried out, using haloperidol as a reference drug to evaluate the antipsychotic efficacy and adverse reactions of remoxipride, a benzamide derivative. Seventy-two patients fulfilling the DSM-III criteria for schizophrenia or schizophreniform disorder were included, 39 patients in the remoxipride and 33 in the haloperidol group. No significant differences in efficacy were found between the two treatments. Treatment-emergent extrapyramidal symptoms, such as akathisia and rigidity, and drowsiness and increased sleep were significantly more frequent during treatment with haloperidol than during treatment with remoxipride. Thus, remoxipride seems to be as effective as haloperidol after 6 weeks of treatment and has fewer side effects